Marc Gitzinger speaking at World Antimicrobial Resistance Congress

Marc Gitzinger, CEO, BioVersys 


What do you see as the biggest challenges facing the AMR space into 2022?

The biggest challenge in AMR remains the broken reimbursement system in the major Pharma markets.  


If you could wave a magic wand, what would you like to see occur in the coming year to further combat AMR?

Get the Pasteur act through congress and approved. To combat AMR efficiently in the years to come and bring novel products to market, we need a significant Pull mechanism like the Pasteur act to be in place.  


What would you like to highlight about your work/your organization for this coming year?

BioVersys will move two programs into Clinical Phase II studies in 2022, so really exciting times for us. One program is focused on VABP and HABP caused by carbapenem resistant Acinetobacter and the other program is developing a novel anti-tuberculosis drug with really fact bactericidal activity, which is a real differentiator in this disease.  


Do you have any predictions for the AMR space in 2022 and beyond? Any calls-to-action you’d like to highlight?

Focus on patient utility first when evaluating AMR products. Policy makers must put the proposals for Pull mechanisms into action Keep persisting as we will change the environment for AMR products. It is the only chance we have to safeguard modern medicine, as we need access to working antibiotics Venture capital: stop looking at what happened between 2015-2020, analyze the issues that some of the products had and focus on AMR company valuations in 2025 rather than the past.





To Sponsor Or Exhibit


Semen Sen
+1 646.619.1793



To Speak


Emma Goaley
+1 646.400.2576



Press & Media Partnerships


Ipek Coskun
+1 407.421.5818